Related references
Note: Only part of the references are listed.Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
Ding Zhang et al.
CANCER AND METASTASIS REVIEWS (2015)
Hepatic myeloid-derived suppressor cells in cancer
Jose Medina-Echeverz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
Fan Yan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Joseph A. Califano et al.
CLINICAL CANCER RESEARCH (2015)
Significant Roles of Regulatory T Cells and Myeloid Derived Suppressor Cells in Hepatitis B Virus Persistent Infection and Hepatitis B Virus-Related HCCs
Yasuteru Kondo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
The yin and yang of evasion and immune activation in HCC
Oxana V. Makarova-Rusher et al.
JOURNAL OF HEPATOLOGY (2015)
Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)
Koji Kurose et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients
Maria Napolitano et al.
ONCOTARGET (2015)
CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma
Shreya Sharman et al.
FRONTIERS IN IMMUNOLOGY (2015)
Regramming myeloid responses to improve cancer immunotherapy
Yu Zhu et al.
ONCOIMMUNOLOGY (2015)
Presence of circulating Her2-reactive CD8+T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients
Jithendra Kini Bailur et al.
BREAST CANCER RESEARCH (2015)
Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
Manja Idorn et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer
Eva Pastille et al.
CANCER RESEARCH (2014)
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1-or Melan-A-Specific T Cells
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2014)
Molecular Pathways: Myeloid Complicity in Cancer
Ingunn M. Stromnes et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
Ingunn M. Stromnes et al.
GUT (2014)
Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+ T-Cell Responses in Hepatocellular Carcinoma
Tobias Flecken et al.
HEPATOLOGY (2014)
Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions
Tai Hato et al.
HEPATOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma
Yong Huang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2014)
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Hiroshi Yano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
The targeting of immunosuppressive mechanisms in hematological malignancies
M. H. Andersen
LEUKEMIA (2014)
Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
C. Marcelo Diaz-Montero et al.
SEMINARS IN ONCOLOGY (2014)
Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis
Hong-Qiang Zhao et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tumor-associated antigen specific CD8+ T cells in hepatocellular carcinoma - a promising target for immunotherapy
Nathalie Schmidt et al.
ONCOIMMUNOLOGY (2014)
Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
Fumitaka Arihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Yumeng Mao et al.
CANCER RESEARCH (2013)
Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
Suresh Kalathil et al.
CANCER RESEARCH (2013)
Another Armed CD4+ T Cell Ready to Battle Hepatocellular Carcinoma
Roniel Cabrera et al.
HEPATOLOGY (2013)
Impairment of CD4+ Cytotoxic T Cells Predicts Poor Survival and High Recurrence Rates in Patients With Hepatocellular Carcinoma
Junliang Fu et al.
HEPATOLOGY (2013)
The role of MDSCs in hepatocellular carcinoma - in vivo veritas?
Joerg Schrader
JOURNAL OF HEPATOLOGY (2013)
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression
Samuel T. Haile et al.
JOURNAL OF IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages
Daria Capece et al.
BIOMED RESEARCH INTERNATIONAL (2013)
High immunosuppressive burden in advanced hepatocellular carcinoma patients Can effector functions be restored?
Amit A. Lugade et al.
ONCOIMMUNOLOGY (2013)
History of myeloid-derived suppressor cells
James E. Talmadge et al.
NATURE REVIEWS CANCER (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
F Korangy et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
